uniQure Stock
uniQure N.V.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Netherlands
- CEO
- Matthew C. Kapusta
- Employees
- 221
- Market cap
- $1.5 B
- IPO
- 05/02/2014
uniQure N.V. operates in the healthcare and biotechnology sector and is headquartered in the Netherlands. The company's focus lies in developing gene therapies for rare and serious conditions, such as Hemophilia B through its product HEMGENIX. Further research activities involve candidates like AMT-130 for…
AI-generated company profile based on the figures on this page, last updated on 04/08/2026. Not investment advice.
uniQure stock: price history
1D
-3.3%
1W
-3.6%
1M
-48.7%
6M
+23.9%
YTD
-9.0%
1Y
-63.7%
2Y
+236.6%
5Y
-27.5%
10Y
+200.4%
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~40% stronger price swings than usual
uniQure stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 26/08/2026.
Ask the agents about uniQure
Analyst assessment of uniQure
PRICE TARGET LOW
US$28.00
CONSENSUS
US$52.18
MEDIAN
US$48.00
PRICE TARGET HIGH
US$80.00
1
STRONG BUY
31
BUY
6
HOLD
0
SELL
0
STRONG SELL
38
TOTAL · Buy
As of: 05/10/2026
uniQure stock metrics
P/E
-5.39
P/B
4.45
EV/EBITDA
-6.41
RETURN ON EQUITY
-25.0%
NET MARGIN
-1,387.8%
DEBT/EQUITY
0.19
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
82.9%
FLOAT SHARES
57,524,872
AVG. DAILY VOLUME (30D)
2,887,831
Insider transactions (SEC)
Kapusta Matthew C
Kapusta Matthew C
Kapusta Matthew C
Kapusta Matthew C
Kaye Jack
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -3.3%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about uniQure stock
What does uniQure do?
uniQure N.V. is a company in the Healthcare sector, Biotechnology industry, headquartered in Netherlands.
The CEO is Matthew C. Kapusta, the company employs around 221 people.
The IPO was on 05/02/2014; the stock trades on NASDAQ under the ticker QURE.
What do analysts say about uniQure stock?
38 analysts rate the stock, the consensus is Buy (as of 05/10/2026).
The average price target is US$52.18, ranging from US$28.00 to US$80.00, with a median of US$48.00.
This is an external assessment, not a statement by Market Jury.
When does uniQure report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 40% stronger than usual.
Does uniQure pay a dividend?
No, uniQure currently does not pay a dividend.
Which stocks are comparable to uniQure?
Comparable stocks include argenx, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get uniQure stock analyzed?
Clicking "Analyze stock" lets five strategies assess uniQure against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.